Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis

Abstract Background Remodeling of the extracellular matrix (ECM) is a central mechanism in the progression of idiopathic pulmonary fibrosis (IPF), and remodeling of type VI collagen has been suggested to be associated with disease progression. Biomarkers that reflect and predict the progression of I...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Henrik Jessen, Nils Hoyer, Thomas S. Prior, Peder Frederiksen, Sarah R. Rønnow, Morten A. Karsdal, Diana J. Leeming, Elisabeth Bendstrup, Jannie M. B. Sand, Saher B. Shaker
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Type VI collagen Biomarkers Cohort study Extracellular matrix Idiopathic pulmonary fibrosis Diseases of the respiratory system RC705-779
Acceso en línea:	https://doaj.org/article/51e299aa98f7485bbe5ebc94f9457fa2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:51e299aa98f7485bbe5ebc94f9457fa2
record_format	dspace
spelling	oai:doaj.org-article:51e299aa98f7485bbe5ebc94f9457fa22021-11-28T12:36:26ZLongitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis10.1186/s12890-021-01684-31471-2466https://doaj.org/article/51e299aa98f7485bbe5ebc94f9457fa22021-11-01T00:00:00Zhttps://doi.org/10.1186/s12890-021-01684-3https://doaj.org/toc/1471-2466Abstract Background Remodeling of the extracellular matrix (ECM) is a central mechanism in the progression of idiopathic pulmonary fibrosis (IPF), and remodeling of type VI collagen has been suggested to be associated with disease progression. Biomarkers that reflect and predict the progression of IPF would provide valuable information for clinicians when treating IPF patients. Methods Two serological biomarkers reflecting formation (PRO-C6) and degradation (C6M) of type VI collagen were evaluated in a real-world cohort of 178 newly diagnoses IPF patients. All patients were treatment naïve at the baseline visit. Blood samples and clinical data were collected from baseline, six months, and 12 months visit. The biomarkers were measured by competitive ELISA using monoclonal antibodies. Results Patients with progressive disease had higher (P = 0.0099) serum levels of PRO-C6 compared to those with stable disease over 12 months with an average difference across all timepoints of 12% (95% CI 3–22), whereas C6M levels tended (P = 0.061) to be higher in patients with progressive disease compared with stable patients over 12 months with an average difference across all timepoints of 12% (95% CI − 0.005–27). Patients who did not receive antifibrotic medicine had a greater increase of C6M (P = 0.043) compared to treated patients from baseline over 12 months with an average difference across all timepoints of 12% (95% CI − 0.07–47). There were no differences in biomarker levels between patients receiving pirfenidone or nintedanib. Conclusions Type VI collagen formation was related to progressive disease in patients with IPF in a real-world cohort and antifibrotic therapy seemed to affect the degradation of type VI collagen. Type VI collagen formation and degradation products might be potential biomarkers for disease progression in IPF.Henrik JessenNils HoyerThomas S. PriorPeder FrederiksenSarah R. RønnowMorten A. KarsdalDiana J. LeemingElisabeth BendstrupJannie M. B. SandSaher B. ShakerBMCarticleType VI collagenBiomarkersCohort studyExtracellular matrixIdiopathic pulmonary fibrosisDiseases of the respiratory systemRC705-779ENBMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Type VI collagen Biomarkers Cohort study Extracellular matrix Idiopathic pulmonary fibrosis Diseases of the respiratory system RC705-779
spellingShingle	Type VI collagen Biomarkers Cohort study Extracellular matrix Idiopathic pulmonary fibrosis Diseases of the respiratory system RC705-779 Henrik Jessen Nils Hoyer Thomas S. Prior Peder Frederiksen Sarah R. Rønnow Morten A. Karsdal Diana J. Leeming Elisabeth Bendstrup Jannie M. B. Sand Saher B. Shaker Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis
description	Abstract Background Remodeling of the extracellular matrix (ECM) is a central mechanism in the progression of idiopathic pulmonary fibrosis (IPF), and remodeling of type VI collagen has been suggested to be associated with disease progression. Biomarkers that reflect and predict the progression of IPF would provide valuable information for clinicians when treating IPF patients. Methods Two serological biomarkers reflecting formation (PRO-C6) and degradation (C6M) of type VI collagen were evaluated in a real-world cohort of 178 newly diagnoses IPF patients. All patients were treatment naïve at the baseline visit. Blood samples and clinical data were collected from baseline, six months, and 12 months visit. The biomarkers were measured by competitive ELISA using monoclonal antibodies. Results Patients with progressive disease had higher (P = 0.0099) serum levels of PRO-C6 compared to those with stable disease over 12 months with an average difference across all timepoints of 12% (95% CI 3–22), whereas C6M levels tended (P = 0.061) to be higher in patients with progressive disease compared with stable patients over 12 months with an average difference across all timepoints of 12% (95% CI − 0.005–27). Patients who did not receive antifibrotic medicine had a greater increase of C6M (P = 0.043) compared to treated patients from baseline over 12 months with an average difference across all timepoints of 12% (95% CI − 0.07–47). There were no differences in biomarker levels between patients receiving pirfenidone or nintedanib. Conclusions Type VI collagen formation was related to progressive disease in patients with IPF in a real-world cohort and antifibrotic therapy seemed to affect the degradation of type VI collagen. Type VI collagen formation and degradation products might be potential biomarkers for disease progression in IPF.
format	article
author	Henrik Jessen Nils Hoyer Thomas S. Prior Peder Frederiksen Sarah R. Rønnow Morten A. Karsdal Diana J. Leeming Elisabeth Bendstrup Jannie M. B. Sand Saher B. Shaker
author_facet	Henrik Jessen Nils Hoyer Thomas S. Prior Peder Frederiksen Sarah R. Rønnow Morten A. Karsdal Diana J. Leeming Elisabeth Bendstrup Jannie M. B. Sand Saher B. Shaker
author_sort	Henrik Jessen
title	Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis
title_short	Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis
title_full	Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis
title_fullStr	Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis
title_full_unstemmed	Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis
title_sort	longitudinal serological assessment of type vi collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis
publisher	BMC
publishDate	2021
url	https://doaj.org/article/51e299aa98f7485bbe5ebc94f9457fa2
work_keys_str_mv	AT henrikjessen longitudinalserologicalassessmentoftypevicollagenturnoverisrelatedtoprogressioninarealworldcohortofidiopathicpulmonaryfibrosis AT nilshoyer longitudinalserologicalassessmentoftypevicollagenturnoverisrelatedtoprogressioninarealworldcohortofidiopathicpulmonaryfibrosis AT thomassprior longitudinalserologicalassessmentoftypevicollagenturnoverisrelatedtoprogressioninarealworldcohortofidiopathicpulmonaryfibrosis AT pederfrederiksen longitudinalserologicalassessmentoftypevicollagenturnoverisrelatedtoprogressioninarealworldcohortofidiopathicpulmonaryfibrosis AT sarahrrønnow longitudinalserologicalassessmentoftypevicollagenturnoverisrelatedtoprogressioninarealworldcohortofidiopathicpulmonaryfibrosis AT mortenakarsdal longitudinalserologicalassessmentoftypevicollagenturnoverisrelatedtoprogressioninarealworldcohortofidiopathicpulmonaryfibrosis AT dianajleeming longitudinalserologicalassessmentoftypevicollagenturnoverisrelatedtoprogressioninarealworldcohortofidiopathicpulmonaryfibrosis AT elisabethbendstrup longitudinalserologicalassessmentoftypevicollagenturnoverisrelatedtoprogressioninarealworldcohortofidiopathicpulmonaryfibrosis AT janniembsand longitudinalserologicalassessmentoftypevicollagenturnoverisrelatedtoprogressioninarealworldcohortofidiopathicpulmonaryfibrosis AT saherbshaker longitudinalserologicalassessmentoftypevicollagenturnoverisrelatedtoprogressioninarealworldcohortofidiopathicpulmonaryfibrosis
_version_	1718407889353179136

Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis

Ejemplares similares